{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:40:15Z","timestamp":1759452015845,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.vaccine.2022.12.038","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T19:12:38Z","timestamp":1675192358000},"page":"1616-1622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Spontaneous reports of primary ovarian insufficiency after vaccination: A review of the vaccine adverse event reporting system (VAERS)"],"prefix":"10.1016","volume":"41","author":[{"given":"A.","family":"Patricia Wodi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adamma","family":"Mba-Jonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith","family":"Barash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosal","family":"Nguon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.12.038_b0005","first-page":"604","article-title":"Incidence of premature ovarian failure","volume":"67","author":"Coulam","year":"1986","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2022.12.038_b0010","doi-asserted-by":"crossref","unstructured":"The American College of Obstetricians and Gynecologists. Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol. 2014;124(1):193\u2013197.","DOI":"10.1097\/01.AOG.0000451757.51964.98"},{"key":"10.1016\/j.vaccine.2022.12.038_b0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13633-015-0009-z","article-title":"Primary Ovarian Insufficiency in adolescents: a case series","volume":"2015","author":"Pederson","year":"2015","journal-title":"Int J Pediatr Endocrinol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.038_b0020","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jpag.2017.04.003","article-title":"Premature Ovarian Insufficiency: AN Adolescent Series","volume":"30","author":"Chaloutsou","year":"2017","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.038_b0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/MED.0000000000000206","article-title":"Update on Primary Ovarian Insufficiency","volume":"22","author":"Hewlett","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.038_b0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.rbmo.2019.04.019","article-title":"Pregnancy following diagnosis of premature ovarian insufficiency: a systematic review","volume":"39","author":"Fraison","year":"2019","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"10.1016\/j.vaccine.2022.12.038_b0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cge.12921","article-title":"Genetics of primary ovarian insufficiency","volume":"91","author":"Rossetti","year":"2017","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.038_b0040","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1056\/NEJMcp0808697","article-title":"Primary ovarian insufficiency","volume":"360","author":"Nelson","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.038_b0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jpag.2017.07.005","article-title":"Evaluation and Management of Primary Ovarian Insufficiency in Adolescents and Young Adults","volume":"31","author":"Kanj","year":"2018","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.vaccine.2022.12.038_b0050","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1196\/annals.1429.000","article-title":"Premature Ovarian Failure in the adolescent","volume":"1135","author":"Rebar","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"2 Suppl 2","key":"10.1016\/j.vaccine.2022.12.038_b0055","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1016\/j.jaci.2009.09.053","article-title":"Immunologic Endocrine Disorders","volume":"125","author":"Michels","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2022.12.038_b0060","unstructured":"Wraith DC, Goldman M and Lambert P. Vaccination and autoimmune disease: what is the evidence? The Lancet. Published online June 3, 2003. http:\/\/image.thelancet.com\/extras\/02art9340web.pdf."},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.038_b0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/13625187.2019.1702638","article-title":"Prevalence of autoimmune disease in women with premature ovarian failure","volume":"25","author":"Grossmann","year":"2020","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.038_b0070","first-page":"245","article-title":"A clinical research integration special program (CRISP) for young women with primary ovarian insufficiency","volume":"56","author":"Farlorni","year":"2014","journal-title":"Panminerva Med"},{"key":"10.1016\/j.vaccine.2022.12.038_b0075","doi-asserted-by":"crossref","unstructured":"Little DT, Ward HR.Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Rep 2012;2012.","DOI":"10.1136\/bcr-2012-006879"},{"key":"10.1016\/j.vaccine.2022.12.038_b0080","doi-asserted-by":"crossref","unstructured":"Little DT, Ward HR. Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice. J Investig Med High Impact Case Rep 2014;2:2324709614556129.","DOI":"10.1177\/2324709614556129"},{"key":"10.1016\/j.vaccine.2022.12.038_b0085","doi-asserted-by":"crossref","unstructured":"Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune\/inflammatory syndrome induced by adjuvants. AmericanJ Reprod Immunol (New York, NY : 1989) 2013;70:309-16.","DOI":"10.1111\/aji.12151"},{"key":"10.1016\/j.vaccine.2022.12.038_b0090","article-title":"Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2022.12.038_b0095","unstructured":"Centers for Disease Control and Prevention (CDC). Recommended Child and adolescent Immunization schedule for ages 18 years and younger, United States 2022: Advisory Committee on Immunization Practices. https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/child-adolescent.html Accessed March 9, 2021."},{"issue":"5","key":"10.1016\/j.vaccine.2022.12.038_b0100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.amepre.2016.05.013","article-title":"Concomitant Adolescent Vaccination in the U.S., 2007\u20132012","volume":"51","author":"Moss","year":"2016","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2022.12.038_b0105","unstructured":"Scott S. Field, MD. New Concerns about the Human Papillomavirus Vaccine. American College of Pediatricians \u2013 January 2016. Available at https:\/\/acpeds.org\/position-statements\/human-papillomavirus-vaccination-hpv. Accessed March 15, 2021."},{"key":"10.1016\/j.vaccine.2022.12.038_b0110","unstructured":"Wetzstein C. HPV vaccine cited in infertility case: Wis. sisters say drug led to ovarian failure by age 16. The Washington Times 11 11, 2013 Available at: https:\/\/www.washingtontimes.com\/news\/2013\/nov\/11\/hpv-vaccine-cited-in-infertility-case\/. Accessed March 15, 2021."},{"key":"10.1016\/j.vaccine.2022.12.038_b0115","unstructured":"Favoloro M. Young women claim HPV vaccine left them infertile. The Legal Examiner. 12 5, 2013 Available at: http:\/\/norfolk.legalexaminer.com\/fda-prescription-drugs\/young-women-claim-hpv-vaccine-left-them-infertile\/. Accessed March 15, 2021."},{"key":"10.1016\/j.vaccine.2022.12.038_b0120","unstructured":"Jonathan; SaneVax, Inc. Infertility concern with gardasil HPV vaccine: does the HPV vaccine LITERALLY mean \u201cone less\u201d? 2011 Available at: http:\/\/sanevax.org\/infertility-concern-with-gardasil-hpv-vaccine\/. Accessed March 15, 2021."},{"key":"10.1016\/j.vaccine.2022.12.038_b0125","doi-asserted-by":"crossref","unstructured":"Naleway AL, Mittendorf KF, Irving SA, re al. Primary Ovarian Insufficiency and Adolescent Vaccination. Pediatrics. 2018 Sep;142(3). pii: e20180943. doi: 10.1542\/peds.2018-0943. Epub 2018 Aug 21.","DOI":"10.1542\/peds.2018-0943"},{"issue":"36","key":"10.1016\/j.vaccine.2022.12.038_b0130","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.038_b0135","unstructured":"U.S. Code of Federal Regulations, 21 CFR 600.80. Postmarketing reporting of adverse experiences (2014). Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=600.80 Accessed March 15, 2021."},{"issue":"20","key":"10.1016\/j.vaccine.2022.12.038_b0140","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.vaccine.2016.03.049","article-title":"Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011\u20132015","volume":"34","author":"Moro","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.038_b0145","doi-asserted-by":"crossref","first-page":"561.e1","DOI":"10.1016\/j.ajog.2013.12.036","article-title":"Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant women","volume":"210","author":"Moro","year":"2014","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.038_b0150","doi-asserted-by":"crossref","first-page":"478.e1","DOI":"10.1016\/j.ajog.2013.02.027","article-title":"Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System","volume":"208","author":"Zheteyeva","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2022.12.038_b0155","doi-asserted-by":"crossref","unstructured":"DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53(3):177-190. doi:10.2307\/2686093.","DOI":"10.1080\/00031305.1999.10474456"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.038_b0160","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"9","key":"10.1016\/j.vaccine.2022.12.038_b0165","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.24.13.1099.38090","article-title":"Pharmacovigilance in the 21st century: new systematic tools for an old problem","volume":"24","author":"Szarfman","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.038_b0170","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1097\/AOG.0b013e3181a66843","article-title":"Premature Ovarian Failure","volume":"113","author":"Rebar","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"5 Pt 1","key":"10.1016\/j.vaccine.2022.12.038_b0175","first-page":"720","article-title":"Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure","volume":"99","author":"Alzubaidi","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2022.12.038_b0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jpag.2013.12.001","article-title":"Menstruation in adolescents: what do we know? And what do we do with the information?","volume":"27","author":"Hillard","year":"2014","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.vaccine.2022.12.038_b0185","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/GCO.0b013e328364ed2a","article-title":"Primary Ovarian Insufficiency in the adolescent","volume":"25","author":"Baker","year":"2013","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2022.12.038_b0190","doi-asserted-by":"crossref","first-page":"10762","DOI":"10.1038\/s41598-020-67668-1","article-title":"Human papillomavirus vaccine-associated premature ovarian insufficiency and related adverse events: data mining of Vaccine Adverse Event Reporting System","volume":"10","author":"Gong","year":"2020","journal-title":"Sci Rep"},{"issue":"Supplement 1","key":"10.1016\/j.vaccine.2022.12.038_b0195","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1542\/peds.2010-1722I","article-title":"Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink Project","volume":"127","author":"Yih","year":"2011","journal-title":"Pediatrics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:09Z","timestamp":1759404189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22015638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0264410X22015638"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spontaneous reports of primary ovarian insufficiency after vaccination: A review of the vaccine adverse event reporting system (VAERS)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}